Market Overview:
The global human tetanus immunoglobulin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of tetanus, rising demand for human tetanus immunoglobulin in developing countries, and technological advancements in the field of human tetanus immunoglobulin production. However, factors such as high cost of treatment and lack of awareness about preventive measures against tetanus are restraining the growth of this market. Based on type, the global human tetanus immunoglobulin market can be segmented into injection and freeze-dried injection. Injection is further sub-segmented into lyophilized powder and reconstituted solution. Freeze-dried injection is further sub-segmented into dry powder form and frozen form.
Product Definition:
Human Tetanus Immunoglobulin is a preparation of pooled human plasma containing antibodies to the tetanus toxin.
Injection:
Injection is a medical procedure used to deliver medication into the body. Medication can be delivered intravenously, orally or subcutaneously. Injection is also known as inoculation, intradermal injection or skin vaccination and works by allowing active substances to enter the bloodstream through the outer layer of the skin.
The most common form of injections are vaccines for tetanus, diphtheria andpertussis (DPP3 inhibitor).
Freeze-dried Injection:
Freeze-dried injection (FDIn) is a drug delivery system that involves the use of lyophilized (freeze-dried) immunoglobulin in the form of an injectable. It is used to treat human tetanus, also known as byLock disease or byHorner's syndrome. The treatment for human tetanus consists of two injections every four to six weeks.
Application Insights:
Based on the application, the global human tetanus immunoglobulin market is segmented into adults and children. The adult segment held a larger share in 2017 as compared to the child segment. This is due to higher incidence of Tetanus infection among adults as compared to children. According to WHO, every year around 50 million people get infected with Tetanus worldwide and around 150,000 people die due to this condition. Moreover, according these statistics published by WHO in 2018 regarding Tetanus vaccination coverage across various regions globally; it was observed that more than 80% of population were vaccinated against this condition globally but less than 60% of population were vaccinated in some under-vaccinated regions such as South America and Africa which increases chances of getting infected subsequently leading towards higher demand for immunoglobulin therapy for treatment purposes driving the market growth during this period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers coupled with high demand for immunoglobulin based products is expected to drive the regional market over the forecast period. In addition, increasing incidence oflockjaw and rising awareness about immunization programs are anticipated to propel product sales in this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to growing medical tourism industry and improving healthcare infrastructure in emerging countries such as India, China, Thailand, Malaysia & Singapore. In addition, rising prevalence of neonatal jaundice and increasing incidence tetanus cases due lock jaw are also contributing towards regional growth.
Growth Factors:
- Increasing incidence of tetanus across the globe
- Growing demand for human tetanus immunoglobulin in developing countries
- Rising awareness about the benefits of human tetanus immunoglobulin therapy
- Technological advancements in the field of human tetanus immunoglobulin production
- increasing number of research and development activities for novel therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Tetanus Immunoglobulin Market Research Report
By Type
Injection, Freeze-dried Injection
By Application
Adults, Children
By Companies
Baxalta, CSL, Octapharma, Grifols, LFB, Biotest, Kedrion, Hualan Biological Engineering
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Human Tetanus Immunoglobulin Market Report Segments:
The global Human Tetanus Immunoglobulin market is segmented on the basis of:
Types
Injection, Freeze-dried Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxalta
- CSL
- Octapharma
- Grifols
- LFB
- Biotest
- Kedrion
- Hualan Biological Engineering
Highlights of The Human Tetanus Immunoglobulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Freeze-dried Injection
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Tetanus Immunoglobulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human tetanus immunoglobulin is a protein that helps the body fight against tetanus. Tetanus is a serious infection caused by the bacterium Clostridium tetani. The disease can cause severe muscle spasms and even death if not treated quickly. Human tetanus immunoglobulin helps the body build immunity to this infection, so it can better fight off future attacks.
Some of the major players in the human tetanus immunoglobulin market are Baxalta, CSL, Octapharma, Grifols, LFB, Biotest, Kedrion, Hualan Biological Engineering.
The human tetanus immunoglobulin market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Tetanus Immunoglobulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Tetanus Immunoglobulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Tetanus Immunoglobulin Market - Supply Chain
4.5. Global Human Tetanus Immunoglobulin Market Forecast
4.5.1. Human Tetanus Immunoglobulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Tetanus Immunoglobulin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Tetanus Immunoglobulin Market Absolute $ Opportunity
5. Global Human Tetanus Immunoglobulin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
5.3.1. Injection
5.3.2. Freeze-dried Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Tetanus Immunoglobulin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Tetanus Immunoglobulin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Tetanus Immunoglobulin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Tetanus Immunoglobulin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Tetanus Immunoglobulin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Tetanus Immunoglobulin Demand Share Forecast, 2019-2029
9. North America Human Tetanus Immunoglobulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
9.7.1. Injection
9.7.2. Freeze-dried Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Tetanus Immunoglobulin Demand Share Forecast, 2019-2029
10. Latin America Human Tetanus Immunoglobulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
10.7.1. Injection
10.7.2. Freeze-dried Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Tetanus Immunoglobulin Demand Share Forecast, 2019-2029
11. Europe Human Tetanus Immunoglobulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Tetanus Immunoglobulin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
11.7.1. Injection
11.7.2. Freeze-dried Injection
11.8. Basis Point Share (BPS) Analysis by Type
11.. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Tetanus Immunoglobulin Demand Share, 2019-2029
12. Asia Pacific Human Tetanus Immunoglobulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Tetanus Immunoglobulin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
12.7.1. Injection
12.7.2. Freeze-dried Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Tetanus Immunoglobulin Demand Share, 2019-2029
13. Middle East & Africa Human Tetanus Immunoglobulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Tetanus Immunoglobulin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Tetanus Immunoglobulin Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Tetanus Immunoglobulin Market Size and Volume Forecast by Type
13.7.1. Injection
13.7.2. Freeze-dried Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Tetanus Immunoglobulin Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Human Tetanus Immunoglobulin Market: Market Share Analysis
14.2. Human Tetanus Immunoglobulin Distributors and Customers
14.3. Human Tetanus Immunoglobulin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxalta
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CSL
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Octapharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Grifols
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. LFB
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biotest
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kedrion
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hualan Biological Engineering
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
